In addition to the end of the shortage, Eli Lilly announced its intent to reduce prices for Zepbound, offering single-dose vials at $499 per month, down from $699, to keep pricing competitive
[14] [15] Time-course analyses from these trials reveal consistent patterns: initial weight loss begins within 4 weeks, accelerates during dose escalation (weeks 0-20), continues at a steady rate through week 48, and plateaus between weeks 48-72
placebo in 3,127 adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, OSA, or cardiovascular disease, who did not have diabetes
[4] [5] However, there is no established association between semaglutide and acquired hypothyroidism or clinically significant thyroid dysfunction affecting metabolism in humans
Reklama Jakie leki GLP-1 s dostpne w Polsce